Clinical trials: Recurrent Metastases
Metastasis, Locally Advanced Solid Tumor
Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients
XRD-0394 is a novel, potent, oral, small molecule dual inhibitor of ataxia telangiectasia mutated kinase (ATM) and deoxyribonucleic acid (DNA)-dependent protein kinase (DNA-PK) that has selectivity compared with other…
- Conditions
- Metastasis, Locally Advanced Solid Tumor, Recurrent Cancer
- Trial name
- NCT05002140
- Testing
- XRD-0394, Palliative radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- XRad Therapeutics Inc
Graft Versus Host Disease, Leukemia
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
RATIONALE: OTI-010 may be effective for graft-versus-host disease prophylaxis (prevention) in patients who are undergoing donor peripheral stem cell transplantation for hematologic malignancies (cancer of the blood or bone…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00081055
- Testing
- autologous expanded mesenchymal stem cells OTI-010, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- Mesoblast International Sàrl
Gastrointestinal Cancer
Registry of Huaier Granule for Prevention of Recurrence and Metastasis of Gastrointestinal Cancer After Radical Surgery
Registration of patients after gastrointestinal cancer radical surgery, including the information of treatments, recurrence \& metastasis, adverse events,etc.
- Trial name
- NCT02975661
- Where
- 12 sites in China
- Volunteers
- 740 people
- Sponsor
- Qidong Gaitianli Medicines Co., Ltd
Multiple Sclerosis
12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients
This is a 12-week study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral CS-0777 in patients with Multiple Sclerosis.
- Trial name
- NCT00616733
- Testing
- CS-0777 tablets
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Daiichi Sankyo
Ovarian Cancer, Ovarian Neoplasms
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
This study, ELU- FRα-1, was focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific…
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer
- Trial name
- NCT05001282
- Testing
- ELU001
- Where
- 18 sites in United States
- Volunteers
- 79 people
- Sponsor
- Elucida Oncology
Urologic Neoplasms
Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients locally advanced, metastatic, or recurrent transitional cell…
- Trial name
- NCT00034177
- Testing
- S-8184 Paclitaxel Injectable Emulsion, Experimental Arm: TOCOSOL Paclitaxel
- Volunteers
- 27 people
- Sponsor
- Achieve Life Sciences
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
- Trial name
- NCT05156281
- Testing
- Remibrutinib, Teriflunomide
- Where
- 223 sites in United States, Argentina and 25 more
- Volunteers
- 1,007 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Adenocarcinoma
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
This is a Phase 1b/2 study of batiraxcept (AVB-S6-500) designed to evaluate the safety and efficacy of batiraxcept in combination with nab-paclitaxel and gemcitabine in subjects with locally advanced, recurrent, or metastatic…
- Trial name
- NCT04983407
- Testing
- batiraxcept, Nab paclitaxel, Gemcitabine
- Where
- 17 sites in United States
- Volunteers
- 34 people
- Sponsor
- Aravive, Inc.
Solid Tumors, CNS Tumors
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain…
- Trial name
- STARTRK-NG (NCT02650401)
- Testing
- Entrectinib
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasm, Brain Neoplasm
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
The purpose of this study is to determine whether temozolomide can be used as a prophylaxis against brain recurrence in participants with metastatic breast cancer.
- Conditions
- Breast Neoplasm, Brain Neoplasm, Second Neoplasm
- Trial name
- STOP (NCT00638963)
- Testing
- temozolomide
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, when administered alone and in combination with low-dose cytarabine (LDAC) or Decitabine for the treatment of adults with Acute Myeloid Leukemia (AML)…
- Trial name
- NCT04113616
- Testing
- KRT-232, Cytarabine, Decitabine
- Where
- 59 sites in United States, Australia and 10 more
- Volunteers
- 70 people
- Sponsor
- Kartos Therapeutics, Inc.
Cancer, Carcinoma
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects with recurrent ovarian cancer.
- Conditions
- Cancer, Carcinoma, Fallopian Tube Cancer, Gynecological Malignancies
- Trial name
- NCT00770536
- Testing
- A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 103 people
- Sponsor
- Amgen
Non-small-cell Lung Carcinoma
The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring
The purpose of this study is to assess the value of circulating tumor cells (CTC)for non-small cell lung cancer in the postoperative recurrence monitoring by comparing the CTCs, CT and tumor markers at different time points.The…
- Trial name
- NCT02647164
- Volunteers
- 360 people
- Sponsor
- GenoSaber
Head and Neck Cancer, Oral Complications
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by…
- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00017511
- Testing
- cevimeline hydrochloride
- Where
- 71 sites in United States
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumors
Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors
This is a Phase I dose escalation study of TCD-717, a novel drug that is a specific inhibitor of the enzyme choline kinase alpha, in patients with advanced solid tumors.
- Trial name
- NCT01215864
- Testing
- TCD-717
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Traslational Cancer Drugs Pharma, SL
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer.
- Trial name
- FIERCE-HN (NCT06064877)
- Testing
- Ficlatuzumab, Cetuximab
- Where
- 112 sites in United States, Australia and 16 more
- Volunteers
- 410 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Advanced Solid Tumors, Acute Myeloid Leukaemia (AML)
RVU120 Rollover Study
This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when…
- Conditions
- Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
- Trial name
- ROVER-01 (NCT06987058)
- Testing
- RVU120, Ruxolitinib
- Where
- 7 sites in France, Poland
- Volunteers
- 14 people
- Sponsor
- Ryvu Therapeutics SA
Squamous Cell Cancer
Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
The purpose of this open-label, randomized, controlled, Phase 1/2 study of the integrin inhibitor cilengitide is to evaluate the safety and efficacy of the combination of different regimens of cilengitide added to cisplatin…
- Trial name
- ADVANTAGE (NCT00705016)
- Testing
- Cilengitide 2000 mg once weekly, Cilengitide 2000 mg twice weekly, Cetuximab
- Where
- 37 sites in Austria, Belgium and 7 more
- Volunteers
- 184 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Refractory Cancer, Recurrent Cancer
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
This screening study will identify HLA molecular subtype positive and tumor antigen target(s) positive patients who may be eligible for enrollment into Immatics clinical studies.
- Conditions
- Refractory Cancer, Recurrent Cancer, Adult Solid Tumor, Neoplasms
- Trial name
- NCT03760952
- Where
- 4 sites in United States
- Volunteers
- 242 people
- Sponsor
- Immatics US, Inc.
Solid Tumors
To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550
This study will assess the safety, tolerability, and PK of INCB086550 and determine the Maximum Tolerated Dose (MTD) and/or recommended Phase 2 Dose(RP2D) of INCB086550, whichever is lower, in Japanese participants with advanced…
- Trial name
- NCT04674748
- Testing
- INCB086550
- Where
- 2 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Incyte Biosciences Japan GK